Nanosphere Inc (NSPH) 0.84 $NSPH
Nanosphere's Verigene BC-GP Decreases Patient Length of Stay
GlobeNewswire - Thu Mar 03, 7:00AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company's FDA-cleared Verigene(R) Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population.
NSPH: 0.84 (-0.03)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Jan 08, 7:32AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
QUAD: 12.79 (-0.11), TLN: 7.81 (+0.15), MOBL: 3.98 (+0.05), NSPH: 0.84 (-0.03)
Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results
GlobeNewswire - Wed Jan 06, 3:01PM CST
-- Preliminary Fourth Quarter Revenue of $6.8 Million
NSPH: 0.84 (-0.03)
Verigene(R) BC-GN Positioned to Provide Rapid Diagnosis of "Phantom Menace" Superbug
GlobeNewswire - Wed Dec 23, 7:00AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, confirms that the Verigene(R) Gram-Negative Blood Culture Test (BC-GN) is the only FDA-cleared test with the ability to rapidly identify the antibiotic resistance gene associated with a dangerous new superbug.
NSPH: 0.84 (-0.03)
Nanosphere, Inc. Announces Completion of $10 Million Registered Public Offering
GlobeNewswire - Tue Dec 22, 3:04PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, today announced the completion of its previously announced public offering of the company's common stock for total gross proceeds of approximately $10 million.
NSPH: 0.84 (-0.03)
Nanosphere, Inc. Announces $10 Million Registered Public Offering
GlobeNewswire - Thu Dec 17, 5:32PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, today announced the pricing of a public offering of the company's common stock with expected total gross proceeds of approximately $10 million. The offering is expected to close on or about December 22, 2015, subject to satisfaction of customary closing conditions.
NSPH: 0.84 (-0.03)
Nanosphere Announces Record Q3 2015 Results
GlobeNewswire - Mon Nov 09, 3:01PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today reported financial and operating results for the third quarter ended September 30, 2015.
NSPH: 0.84 (-0.03)
Colorectal Cancer - Pipeline Review, 2015
M2 - Tue Nov 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/qnddjp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Colorectal Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Colorectal Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Colorectal Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Reasons to buy The report enables you to - - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Colorectal Cancer diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Colorectal Cancer - Pipeline Products under Development by Companies 5 Colorectal Cancer Companies and Product Overview 6 Colorectal Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 100 Companies Featured - A2K Technologies - Abbott Diagnostics - Advanced Marker Discovery, S.L. - Advpharma Inc. - Ambergen, Inc. - Ceres Nanosciences, Inc. - Cernostics Inc. - ChemImage Corporation - Nanosphere, Inc. - Neogenix Oncology, Inc. - NetScientific Plc - Norda ASA - Novel Bio-spectrum Technologies, Inc. - Nuclea Biotechnologies Inc. - Nuvera Biosciences, Inc. - OncoVista Innovative Therapies, Inc. - Origin Sciences Limited - Orion Genomics LLC - OTraces Inc. - Oxford Cancer Biomarkers - Oxford Gene Technology Limited - Pacific Edge Limited - Panacea Pharmaceuticals, Inc. - Sysmex Corporation - Universite De Lyon - University of Alabama at Birmingham - University of Chicago - University of Texas at Austin - US Biomarkers, Inc. - Vanderbilt University - Vermillion, Inc. - Viomics Inc. - Vitatex Inc. - VolitionRX Ltd. - XEPTAGEN SpA For more information visit http://www.researchandmarkets.com/research/qn...tal_cancer
VNRX: 3.55 (+0.10), VRML: 1.55 (-0.10), NSPH: 0.84 (-0.03)
Nanosphere to Announce Third Quarter Financial Results & Host Investor Call on Monday, November 9
GlobeNewswire - Mon Nov 02, 7:01AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced today that it will report its results for the third quarter ended September 30, 2015 after the market close on Monday, November 9, 2015. The company will also hold a live investor conference call and webcast at 5pm Eastern Time.
NSPH: 0.84 (-0.03)
Impact of Verigene Blood Culture Tests Highlighted by Five Studies Presented at ICAAC 2015
GlobeNewswire - Tue Sep 22, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced that new clinical data for the Verigene(R) Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests for rapid sepsis diagnostics were presented during Sepsis Awareness Month at the 55 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held last week in San Diego, CA.
NSPH: 0.84 (-0.03)
Nanosphere (NSPH) Stock Soars After FDA Clearance for Flexible Respiratory Pathogens Test
at The Street - Tue Sep 08, 10:59AM CDT
Nanosphere (NSPH) shares are skyrocketing Tuesday morning after the company received clearance from the Food and Drug Administration for its flexible respiratory pathogens test.
NSPH: 0.84 (-0.03)
Nanosphere Receives FDA Clearance for First-of-Its-Kind Flexible Respiratory Pathogens Test
GlobeNewswire - Tue Sep 08, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing the practice of medicine through targeted molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Verigene(R) Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) on the automated sample-to-result Verigene System.
NSPH: 0.84 (-0.03)
Nanosphere Announces Amendment to $30 Million Term Loan Facility, Release of Q2 2015 Results and Conference Call and Schedules 2015 Annual Meeting of Stockholders
GlobeNewswire - Fri Jul 31, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced today that it has amended certain terms of its $30 million term loan facility with NSPH Funding LLC, an affiliate of Life Sciences Alternative Funding LLC, and SWK Funding LLC, as lenders (together, the "Lenders"
. Nanosphere entered into the loan facility and immediately drew $20 million under the facility on May 14, 2015. Under the original terms of the loan facility, Nanosphere was subject to a condition precedent and a post-closing covenant that required Nanosphere to raise an aggregate of at least $4 million in net proceeds from equity financings prior to entering into the loan facility and an aggregate of at least $6 million in net proceeds either equity financings or licensing or strategic partnership transactions within eight months of May 14, 2015, pursuant to which Nanosphere raised an aggregate of $8 million in net proceeds from its preferred stock offerings in May and June 2015. Under the amended terms of the loan facility, the lenders have waived the requirement that Nanopshere raise an additional $2 million in consideration of certain adjustments to the reserve requirements under the loan facility.
NSPH: 0.84 (-0.03)
5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 18, 11:30AM CDT
These under-$10 stocks are setting up to break out and trade higher from current levels.
FBIO: 2.94 (-0.01), NLST: 1.18 (+0.03), EGY: 1.19 (+0.01), NSPH: 0.84 (-0.03)
Nanosphere raises $4M in direct offering
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 4:41PM CDT
NSPH: 0.84 (-0.03)
Nanosphere Announces $4.4 Million at the Market Registered Direct Offering
GlobeNewswire - Mon Jun 08, 3:14PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced today that it has entered into a definitive agreement with a dedicated healthcare institutional investor in a registered direct offering for $4.4 million of convertible preferred stock (which are convertible into a total of 1,203,830 shares of common stock at a conversion price of $3.655) and warrants to purchase shares of common stock exercisable for up to 1,203,830 additional shares of common stock, in the aggregate. The warrants have an exercise price of $3.54 per share and are exercisable for 5 years commencing six months from the closing date. The preferred stock is perpetual and does not have a required dividend right or voting rights and has a liquidation preference of $0.01 per share. The preferred stock has a limitation on conversion into common stock to preclude the holder from acquiring beneficial ownership of more than 4.99% of our outstanding common stock, which may be increased to 9.99% in certain circumstances.
NSPH: 0.84 (-0.03)
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake
ACCESSWIRE - Mon Jun 01, 10:18AM CDT
WINDSOR, ON / ACCESSWIRE / June 1, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
FDX: 143.91 (+0.05), ROSG: 1.23 (unch), PIP: 1.67 (-0.01), NSPH: 0.84 (-0.03)
Eighteen New Verigene Clinical and Economic Studies Presented at CVS, ECCMID and MAD-ID 2015
GlobeNewswire - Wed May 27, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that 18 studies performed by various U.S. and international hospitals were recently presented at the annual Clinical Virology Symposium (CVS) in Daytona Beach, Florida, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, and the Making a Difference in Infectious Diseases (MAD-ID) Conference in Orlando, Florida.
NSPH: 0.84 (-0.03)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed May 27, 8:18AM CDT
HYGS: 8.47 (-0.14), MNGA: 1.25 (+0.02), PLUG: 2.11 (-0.11), ZGNX: 10.17 (-0.30), EOX: 1.08 (+0.10), KORS: 57.16 (-0.03), TIF: 69.77 (+0.67), BZUN: 5.89 (+0.50), OXGN: 0.64 (+0.05), GBIM: 0.97 (-0.13), GBSN: 0.14 (-0.01), ICAD: 4.33 (-0.11), WDAY: 73.11 (-1.19), CLLS: 26.29 (-0.12), RTRX: 14.87 (+0.35), GALE: 0.98 (+0.03), CBLI: 3.45 (+0.02), CHS: 12.80 (-0.25), FPRX: 34.53 (+1.04), MERU: 1.62 (-0.01), NSPH: 0.84 (-0.03)
Nanosphere's Verigene BC-GP Decreases Patient Length of Stay
GlobeNewswire - Thu Mar 03, 7:00AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company's FDA-cleared Verigene(R) Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population.
NSPH: 0.84 (-0.03)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Fri Jan 08, 7:32AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
QUAD: 12.79 (-0.11), TLN: 7.81 (+0.15), MOBL: 3.98 (+0.05), NSPH: 0.84 (-0.03)
Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results
GlobeNewswire - Wed Jan 06, 3:01PM CST
-- Preliminary Fourth Quarter Revenue of $6.8 Million
NSPH: 0.84 (-0.03)
Verigene(R) BC-GN Positioned to Provide Rapid Diagnosis of "Phantom Menace" Superbug
GlobeNewswire - Wed Dec 23, 7:00AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, confirms that the Verigene(R) Gram-Negative Blood Culture Test (BC-GN) is the only FDA-cleared test with the ability to rapidly identify the antibiotic resistance gene associated with a dangerous new superbug.
NSPH: 0.84 (-0.03)
Nanosphere, Inc. Announces Completion of $10 Million Registered Public Offering
GlobeNewswire - Tue Dec 22, 3:04PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, today announced the completion of its previously announced public offering of the company's common stock for total gross proceeds of approximately $10 million.
NSPH: 0.84 (-0.03)
Nanosphere, Inc. Announces $10 Million Registered Public Offering
GlobeNewswire - Thu Dec 17, 5:32PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, today announced the pricing of a public offering of the company's common stock with expected total gross proceeds of approximately $10 million. The offering is expected to close on or about December 22, 2015, subject to satisfaction of customary closing conditions.
NSPH: 0.84 (-0.03)
Nanosphere Announces Record Q3 2015 Results
GlobeNewswire - Mon Nov 09, 3:01PM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today reported financial and operating results for the third quarter ended September 30, 2015.
NSPH: 0.84 (-0.03)
Colorectal Cancer - Pipeline Review, 2015
M2 - Tue Nov 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/qnddjp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Colorectal Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Colorectal Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Colorectal Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Reasons to buy The report enables you to - - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Colorectal Cancer diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Colorectal Cancer - Pipeline Products under Development by Companies 5 Colorectal Cancer Companies and Product Overview 6 Colorectal Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 100 Companies Featured - A2K Technologies - Abbott Diagnostics - Advanced Marker Discovery, S.L. - Advpharma Inc. - Ambergen, Inc. - Ceres Nanosciences, Inc. - Cernostics Inc. - ChemImage Corporation - Nanosphere, Inc. - Neogenix Oncology, Inc. - NetScientific Plc - Norda ASA - Novel Bio-spectrum Technologies, Inc. - Nuclea Biotechnologies Inc. - Nuvera Biosciences, Inc. - OncoVista Innovative Therapies, Inc. - Origin Sciences Limited - Orion Genomics LLC - OTraces Inc. - Oxford Cancer Biomarkers - Oxford Gene Technology Limited - Pacific Edge Limited - Panacea Pharmaceuticals, Inc. - Sysmex Corporation - Universite De Lyon - University of Alabama at Birmingham - University of Chicago - University of Texas at Austin - US Biomarkers, Inc. - Vanderbilt University - Vermillion, Inc. - Viomics Inc. - Vitatex Inc. - VolitionRX Ltd. - XEPTAGEN SpA For more information visit http://www.researchandmarkets.com/research/qn...tal_cancer
VNRX: 3.55 (+0.10), VRML: 1.55 (-0.10), NSPH: 0.84 (-0.03)
Nanosphere to Announce Third Quarter Financial Results & Host Investor Call on Monday, November 9
GlobeNewswire - Mon Nov 02, 7:01AM CST
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced today that it will report its results for the third quarter ended September 30, 2015 after the market close on Monday, November 9, 2015. The company will also hold a live investor conference call and webcast at 5pm Eastern Time.
NSPH: 0.84 (-0.03)
Impact of Verigene Blood Culture Tests Highlighted by Five Studies Presented at ICAAC 2015
GlobeNewswire - Tue Sep 22, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced that new clinical data for the Verigene(R) Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests for rapid sepsis diagnostics were presented during Sepsis Awareness Month at the 55 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held last week in San Diego, CA.
NSPH: 0.84 (-0.03)
Nanosphere (NSPH) Stock Soars After FDA Clearance for Flexible Respiratory Pathogens Test
at The Street - Tue Sep 08, 10:59AM CDT
Nanosphere (NSPH) shares are skyrocketing Tuesday morning after the company received clearance from the Food and Drug Administration for its flexible respiratory pathogens test.
NSPH: 0.84 (-0.03)
Nanosphere Receives FDA Clearance for First-of-Its-Kind Flexible Respiratory Pathogens Test
GlobeNewswire - Tue Sep 08, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing the practice of medicine through targeted molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Verigene(R) Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) on the automated sample-to-result Verigene System.
NSPH: 0.84 (-0.03)
Nanosphere Announces Amendment to $30 Million Term Loan Facility, Release of Q2 2015 Results and Conference Call and Schedules 2015 Annual Meeting of Stockholders
GlobeNewswire - Fri Jul 31, 7:00AM CDT
Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced today that it has amended certain terms of its $30 million term loan facility with NSPH Funding LLC, an affiliate of Life Sciences Alternative Funding LLC, and SWK Funding LLC, as lenders (together, the "Lenders"
. Nanosphere entered into the loan facility and immediately drew $20 million under the facility on May 14, 2015. Under the original terms of the loan facility, Nanosphere was subject to a condition precedent and a post-closing covenant that required Nanosphere to raise an aggregate of at least $4 million in net proceeds from equity financings prior to entering into the loan facility and an aggregate of at least $6 million in net proceeds either equity financings or licensing or strategic partnership transactions within eight months of May 14, 2015, pursuant to which Nanosphere raised an aggregate of $8 million in net proceeds from its preferred stock offerings in May and June 2015. Under the amended terms of the loan facility, the lenders have waived the requirement that Nanopshere raise an additional $2 million in consideration of certain adjustments to the reserve requirements under the loan facility. NSPH: 0.84 (-0.03)
5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 18, 11:30AM CDT
These under-$10 stocks are setting up to break out and trade higher from current levels.
FBIO: 2.94 (-0.01), NLST: 1.18 (+0.03), EGY: 1.19 (+0.01), NSPH: 0.84 (-0.03)
Nanosphere raises $4M in direct offering
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 4:41PM CDT
NSPH: 0.84 (-0.03)
Nanosphere Announces $4.4 Million at the Market Registered Direct Offering
GlobeNewswire - Mon Jun 08, 3:14PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced today that it has entered into a definitive agreement with a dedicated healthcare institutional investor in a registered direct offering for $4.4 million of convertible preferred stock (which are convertible into a total of 1,203,830 shares of common stock at a conversion price of $3.655) and warrants to purchase shares of common stock exercisable for up to 1,203,830 additional shares of common stock, in the aggregate. The warrants have an exercise price of $3.54 per share and are exercisable for 5 years commencing six months from the closing date. The preferred stock is perpetual and does not have a required dividend right or voting rights and has a liquidation preference of $0.01 per share. The preferred stock has a limitation on conversion into common stock to preclude the holder from acquiring beneficial ownership of more than 4.99% of our outstanding common stock, which may be increased to 9.99% in certain circumstances.
NSPH: 0.84 (-0.03)
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake
ACCESSWIRE - Mon Jun 01, 10:18AM CDT
WINDSOR, ON / ACCESSWIRE / June 1, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
FDX: 143.91 (+0.05), ROSG: 1.23 (unch), PIP: 1.67 (-0.01), NSPH: 0.84 (-0.03)
Eighteen New Verigene Clinical and Economic Studies Presented at CVS, ECCMID and MAD-ID 2015
GlobeNewswire - Wed May 27, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that 18 studies performed by various U.S. and international hospitals were recently presented at the annual Clinical Virology Symposium (CVS) in Daytona Beach, Florida, the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, and the Making a Difference in Infectious Diseases (MAD-ID) Conference in Orlando, Florida.
NSPH: 0.84 (-0.03)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed May 27, 8:18AM CDT
HYGS: 8.47 (-0.14), MNGA: 1.25 (+0.02), PLUG: 2.11 (-0.11), ZGNX: 10.17 (-0.30), EOX: 1.08 (+0.10), KORS: 57.16 (-0.03), TIF: 69.77 (+0.67), BZUN: 5.89 (+0.50), OXGN: 0.64 (+0.05), GBIM: 0.97 (-0.13), GBSN: 0.14 (-0.01), ICAD: 4.33 (-0.11), WDAY: 73.11 (-1.19), CLLS: 26.29 (-0.12), RTRX: 14.87 (+0.35), GALE: 0.98 (+0.03), CBLI: 3.45 (+0.02), CHS: 12.80 (-0.25), FPRX: 34.53 (+1.04), MERU: 1.62 (-0.01), NSPH: 0.84 (-0.03)
